Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...

BridgeBio Pharma has bounced back from the withdrawal of infigratinib in oncology, linking the molecule to a BioMarin-beating ...

Today's biotech news update includes a dramatic vote on MDMA therapy, record drug shortages, bad(?) news for Biomarin, and a ...

For Andrew Hanna, adapting to changing situations on stage teaches him how to adapt to the many challenges in life. The ...

BridgeBio Pharma Inc (NASDAQ:BBIO) announced sustained results from the PROPEL 2 Phase 2 trial of the investigational therapy ...

Little Johnstons star Liz Johnston revealed her reaction to learning that her daughter, Leighton Drew, is a normal-sized baby ...

Mizuho Securities analyst Salim Syed assigned a Buy rating on BridgeBio Pharma (BBIO – Research Report) on June 4 and set a price target ...

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

(Exclusive) She also notes that babies with dwarfism or achondroplasia can have "larger than normal" heads. From a birthing perspective, Liz admits that carrying Leighton was "just more bearable ...

Bridgebio Pharma Inc.’s data from the phase II study with infigratinib in achondroplasia “swings the pendulum of debate ...

Snacking on chips and salsa seems pretty simple, but if you’re a person with disabilities at a local establishment, and the ...

Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price target of ...